BioTech (Nov 2023)

Tracking of Systemic Lupus Erythematosus (SLE) Longitudinally Using Biosensor and Patient-Reported Data: A Report on the Fully Decentralized Mobile Study to Measure and Predict Lupus Disease Activity Using Digital Signals—The OASIS Study

  • Eldon R. Jupe,
  • Gerald H. Lushington,
  • Mohan Purushothaman,
  • Fabricio Pautasso,
  • Georg Armstrong,
  • Arif Sorathia,
  • Jessica Crawley,
  • Vijay R. Nadipelli,
  • Bernard Rubin,
  • Ryan Newhardt,
  • Melissa E. Munroe,
  • Brett Adelman

DOI
https://doi.org/10.3390/biotech12040062
Journal volume & issue
Vol. 12, no. 4
p. 62

Abstract

Read online

(1) Objective: Systemic lupus erythematosus (SLE) is a complex disease involving immune dysregulation, episodic flares, and poor quality of life (QOL). For a decentralized digital study of SLE patients, machine learning was used to assess patient-reported outcomes (PROs), QOL, and biometric data for predicting possible disease flares. (2) Methods: Participants were recruited from the LupusCorner online community. Adults self-reporting an SLE diagnosis were consented and given a mobile application to record patient profile (PP), PRO, and QOL metrics, and enlisted participants received smartwatches for digital biometric monitoring. The resulting data were profiled using feature selection and classification algorithms. (3) Results: 550 participants completed digital surveys, 144 (26%) agreed to wear smartwatches, and medical records (MRs) were obtained for 68. Mining of PP, PRO, QOL, and biometric data yielded a 26-feature model for classifying participants according to MR-identified disease flare risk. ROC curves significantly distinguished true from false positives (ten-fold cross-validation: p p 0.85, p 0.83, p < 0.0001). (4) Conclusions: Regular profiling of patient well-being and biometric activity may support proactive screening for circumstances warranting clinical assessment.

Keywords